Loading...
Bispecific T-cell engaging monoclonal antibodies have emerged as important options for patients with relapsed or refractory (R/R) B-cell malignancies. Investigators now report extended follow-up from an industry-sponsored, multicenter, phase 1/2 trial of mosunetuzumab, a CD20 x CD3 bispecific antibody, in patients with R/R indolent and aggressive B-cell non-Hodgkin lymphoma (iNHL and aNHL).
Mosunetuzumab was administered intravenously in 21-day cycles using a stepped-up dosing schedule in cycle 1, with corticosteroid premedication to mitigate infusion reactions and cytokine release syndrome during the first 2 cycles (optional with subsequent cycles); a dose of 30 mg on day 1 was administered beginning with cycle 3. Patients achieving complet…